Olanzapine tablets (all strengths): Supply issue

Supply issue Active

Due to issues at the manufacturing plant, the supplier will run out of olanzapine (Zypine) tablets. A different brand will be available.

Affected product

Due to an issue at the manufacturing site, there is a supply issue affecting all strengths of Zypine branded olanzapine tablets, 2.5mg (Pharmacode: 2651076), 5mg (Pharmacode: 2651084), and 10mg (Pharmacode: 2651092). 

A similar issue is also affecting the Zypine brand orodispersible tablets.

Community Schedule Listing for olanzapine(external link)

HML Schedule Listing for olanzapine(external link)

People who take olanzapine tablets

To make sure you can continue to access your treatment, we have made APO-Olanzapine brand of olanzapine available. 

You may notice that the Apo-Olanzapine tablet is a light yellow, with different marks etched into it, where Zypine is white.

Same active ingredient, in the same amount

Apo-Olanzapine contains the same active ingredient (olanzapine) in the same amount as Zypine, the brand you usually take. Apo-Olanzapine is designed to work in your body the same way as Zypine.

Medicine not Medsafe reviewed

This medicine has not been reviewed by Medsafe for use in New Zealand. However, it has been approved for use in other countries. Your prescriber will discuss this with you before they prescribe it. You can read more information about unapproved medicine on the Healthify website.

Unapproved medicines | Healthify.nz(external link)

Alternative brand funded 1 September

From 1 September 2026, Pharmac will fund an alternate brand, APO-Olanzapine. These should be available for pharmacies and wholesalers to order from early October 2026. 

.

APO-Olanzapine is not Medsafe approved. It needs to be prescribed and supplied in line with Section 29A of the Medicines Act. 

Patient flyers for download

Prescribing and supplying an unapproved medicine

Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people when there is supply issue affecting the registered brand. 

We know supplying an unapproved medicine is not ideal. In this case, however, this will allow people to continue to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 and 29A medicines – Medsafe website(external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Expected resupply late 2026

Viatris, the supplier of Zypine, expects stock to be available again by the end of 2026.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)

Patient flyers